Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (REACT3)

This study has been completed.
Roche Diagnostics
International Diabetes Center at Park Nicollet
Information provided by (Responsible Party):
HealthPartners Institute Identifier:
First received: November 2, 2010
Last updated: November 30, 2015
Last verified: November 2013
The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

Condition Intervention
Type 2 Diabetes
Device: Continuous Glucose Monitoring (CGM)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of Clinical Decisions and Outcomes Employing a Treat to Target Design for Subjects With Type 2 Diabetes Randomized to Either SMBG or CGM

Resource links provided by NLM:

Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • Percentage Change in Hemoglobin A1c [ Time Frame: 2 week baseline to 18 week final ]

Secondary Outcome Measures:
  • The Secondary Objective is to Determine the Incremental Benefit of CGM for Clinical Decision-making. [ Time Frame: 16 weeks ]

    Outcome will be measured by:

    i. HbA1c ii. Glucose exposure (area under the diurnal median curve) iii. Glucose variability (inter-quartile range) iv. Glucose stability (hourly change in the median curve) v. Incidence of hypoglycemia (degree, duration, frequency)

Enrollment: 124
Study Start Date: October 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CGM Group
Wear an unblinded CGM for 16 weeks.
Device: Continuous Glucose Monitoring (CGM)
Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
Other Names:
  • DexCom SevenPlus CGM
  • AccuChek Aviva blood glucose meter
Active Comparator: SMBG Group
Use SMBG 4 to 7 times a day for 16 weeks.
Device: Continuous Glucose Monitoring (CGM)
Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
Other Names:
  • DexCom SevenPlus CGM
  • AccuChek Aviva blood glucose meter

Detailed Description:

This study involves the use of the following 2 glucose monitoring methods to measure your blood sugar (glucose) levels and help manage type 2 diabetes:

  1. Self Monitoring Blood Glucose (SMBG): blood glucose is measured 4-7 times each day using finger sticks and an AccuChek Aviva blood glucose meter.
  2. Continuous Glucose Monitoring (CGM): blood glucose is measured continuously via the DexCom SevenPlus CGM device. This device has been approved for use by the U.S. Food and Drug Administration (FDA).

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female ≥18 and ≤75 years of age (Upper range to assure dexterity for use of CGM)
  • Clinical diagnosis of type 2 diabetes
  • HbA1c ≥7.0%
  • Diabetes can be treated with any of the following therapies within one month prior to study enrollment: (1) medical nutrition therapy alone or with metformin; (2) sulfonylurea with or without metformin; (3) DPP-4 inhibitor or GLP-1 agonist with or without metformin; or insulin with or without metformin.

Exclusion Criteria:

  • Treated with TZD
  • Administered prednisone or cortisone medications in the previous 30 days
  • Currently pregnant or planning pregnancy during the study period
  • Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
  • HbA1c <7.0%
  • Unable to follow the study protocol
  • Unable to speak, read and write in English
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01237301

United States, Minnesota
International Diabetes Center
Minneapolis, Minnesota, United States, 55416
Sponsors and Collaborators
HealthPartners Institute
Roche Diagnostics
International Diabetes Center at Park Nicollet
Principal Investigator: Roger S. Mazze, PhD International Diabetes Center at Park Nicollet
Principal Investigator: Richard M. Bergenstal, MD International Diabetes Center at Park Nicollet
  More Information

Responsible Party: HealthPartners Institute Identifier: NCT01237301     History of Changes
Other Study ID Numbers: 04034-10-C
Study First Received: November 2, 2010
Results First Received: August 30, 2013
Last Updated: November 30, 2015

Keywords provided by HealthPartners Institute:
Type 2 Diabetes
Continuous Glucose Monitoring

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on May 25, 2017